{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T09:57:04Z","timestamp":1789207024276,"version":"build-2803163510"},"reference-count":52,"publisher":"Elsevier BV","issue":"3","content-domain":{"domain":["lrjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.leukres.2013.11.017","type":"journal-article","created":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T19:31:19Z","timestamp":1385926279000},"page":"361-370","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Sensitivity of SNX2-ABL1 toward tyrosine kinase inhibitors distinct from that of BCR-ABL1"],"prefix":"10.1016","volume":"38","author":[{"given":"Osamu","family":"Tomita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutoshi","family":"Iijima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Ishibashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoo","family":"Osumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichiro","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Okita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobutaka","family":"Kiyokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2013.11.017_bib0005","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/j.1365-2141.2005.05497.x","article-title":"Interphase molecular cytogenetic screening for chromosomal abnormalities of prognostic significance in childhood acute lymphoblastic leukaemia: a UK Cancer Cytogenetics Group Study","volume":"129","author":"Harrison","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2013.11.017_bib0010","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1182\/blood-2012-05-378943","article-title":"Pediatric acute lymphoblastic leukemia: where are we going and how do we get there","volume":"120","author":"Pui","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.11.017_bib0015","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1182\/blood.V77.2.324.324","article-title":"Consistent involvement of the bcr gene by 9;22 breakpoints in pediatric acute leukemias","volume":"77","author":"Suryanarayan","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.11.017_bib0020","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-0609.2011.01586.x","article-title":"ABL1 fusion genes in hematological malignancies: a review","volume":"86","author":"De Braekeleer","year":"2011","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.leukres.2013.11.017_bib0025","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nrc3563","article-title":"Role of ABL family kinases in cancer: from leukaemia to solid tumours","volume":"13","author":"Greuber","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.leukres.2013.11.017_bib0030","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s002770050473","article-title":"Molecular pathogenesis of chronic myeloid leukemia: implications for new therapeutic strategies","volume":"78","author":"Warmuth","year":"1999","journal-title":"Ann Hematol"},{"key":"10.1016\/j.leukres.2013.11.017_bib0035","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood.V70.4.948.948","article-title":"Clinical and biologic hallmarks of the Philadelphia chromosome in childhood acute lymphoblastic leukemia","volume":"70","author":"Ribeiro","year":"1987","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.11.017_bib0040","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1182\/blood-2006-01-024729","article-title":"Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG)","volume":"109","author":"Schultz","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.11.017_bib0045","doi-asserted-by":"crossref","first-page":"5175","DOI":"10.1200\/JCO.2008.21.2514","article-title":"Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study","volume":"27","author":"Schultz","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2013.11.017_bib0050","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/j.1365-2141.2011.08783.x","volume":"154","author":"Rives","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2013.11.017_bib0055","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s11864-013-0234-8","article-title":"Chronic myeloid leukemia: overview of new agents and comparative analysis","volume":"14","author":"Jain","year":"2013","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.leukres.2013.11.017_bib0060","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1182\/blood-2005-11-4386","article-title":"Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)","volume":"108","author":"Wassmann","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.11.017_bib0065","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s11912-012-0247-7","article-title":"Philadelphia-positive acute lymphoblastic leukemia: current treatment options","volume":"14","author":"Liu-Dumlao","year":"2012","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.leukres.2013.11.017_bib0070","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3324\/haematol.2009.015974","article-title":"Current treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"95","author":"Fielding","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2013.11.017_bib0075","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nrc2126","article-title":"Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia","volume":"7","author":"Weisberg","year":"2007","journal-title":"Nat Rev Cancer"},{"issue":"Suppl. 6","key":"10.1016\/j.leukres.2013.11.017_bib0080","doi-asserted-by":"crossref","first-page":"vi42","DOI":"10.1093\/annonc\/mdm223","article-title":"Dasatinib: a new step in molecular target therapy","volume":"18","author":"Olivieri","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.leukres.2013.11.017_bib0085","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2013.11.017_bib0090","doi-asserted-by":"crossref","first-page":"6521","DOI":"10.1182\/blood-2011-05-351403","article-title":"Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"118","author":"Fo\u00e0","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.11.017_bib0095","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.leukres.2007.11.008","article-title":"Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines","volume":"32","author":"Deguchi","year":"2008","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2013.11.017_bib0100","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukaemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2013.11.017_bib0105","doi-asserted-by":"crossref","first-page":"93","DOI":"10.4137\/117739010700200008","article-title":"NS-187 (INNO-406), a Bcr-Abl\/Lyn dual tyrosine kinase inhibitor","volume":"2","author":"Niwa","year":"2007","journal-title":"Anal Chem Insights"},{"key":"10.1016\/j.leukres.2013.11.017_bib0110","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O\u2018Hare","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.leukres.2013.11.017_bib0115","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1158\/0008-5472.CAN-10-3224","article-title":"The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile","volume":"71","author":"Eide","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2013.11.017_bib0120","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.ccr.2011.03.003","article-title":"Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036","volume":"19","author":"Chan","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.leukres.2013.11.017_bib0125","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1038\/leusup.2012.22","article-title":"Second-generation TKIs: which and when","volume":"1","author":"Saglio","year":"2012","journal-title":"Leukemia Suppl"},{"key":"10.1016\/j.leukres.2013.11.017_bib0130","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1365-2141.2010.08457.x","article-title":"Identification of FOXP1 and SNX2 as novel ABL1 fusion partners in acute lymphoblastic leukaemia","volume":"153","author":"Ernst","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2013.11.017_bib0135","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/1098-2264(2000)9999:9999<1::AID-GCC1089>3.0.CO;2-1","article-title":"Molecular cytogenetic and clinical findings in ETV6\/ABL1-positive leukemia","volume":"30","author":"Van Limbergen","year":"2001","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.leukres.2013.11.017_bib0140","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/ng1425","article-title":"Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia","volume":"36","author":"Graux","year":"2004","journal-title":"Nat Genet"},{"key":"10.1016\/j.leukres.2013.11.017_bib0145","doi-asserted-by":"crossref","first-page":"4849","DOI":"10.1182\/blood-2004-12-4897","article-title":"Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32)","volume":"105","author":"De Keersmaecker","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.11.017_bib0150","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/gcc.20541","article-title":"The t(1;9)(p34;q34) and t(8;12)(p11;q15) fuse pre-mRNA processing proteins SFPQ (PSF) and CPSF6 to ABL and FGFR1","volume":"47","author":"Hidalgo-Curtis","year":"2008","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.leukres.2013.11.017_bib0155","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.3324\/haematol.2009.008094","article-title":"A novel dasatinib-sensitive RCSD1-ABL1 fusion transcript in chemotherapy-refractory adult pre-B lymphoblastic leukemia with t(1;9)(q24;q34)","volume":"94","author":"Mustjoki","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2013.11.017_bib0160","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s12185-011-0910-z","article-title":"B lymphoblastic leukemia is sensitive to dexamethasone and tyrosine kinase inhibitors and rapidly evolves clonally by chromosomal translocations","volume":"94","author":"Inokuchi","year":"2011","journal-title":"Int J Hematol"},{"key":"10.1016\/j.leukres.2013.11.017_bib0165","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ccr.2012.06.005","article-title":"Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia","volume":"22","author":"Roberts","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.leukres.2013.11.017_bib0170","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/nrm974","article-title":"Sorting out the cellular functions of sorting nexins","volume":"3","author":"Worby","year":"2002","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.leukres.2013.11.017_bib0175","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1600-0854.2005.00260.x","article-title":"Sorting nexins-unifying trends and new perspectives","volume":"6","author":"Carlton","year":"2005","journal-title":"Traffic"},{"key":"10.1016\/j.leukres.2013.11.017_bib0180","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/cas.12117","article-title":"Sorting nexin 2-mediated membrane trafficking of c-Met contributes to sensitivity of molecular-targeted drugs","volume":"104","author":"Ogi","year":"2013","journal-title":"Cancer Sci"},{"key":"10.1016\/j.leukres.2013.11.017_bib0185","doi-asserted-by":"crossref","DOI":"10.1111\/ejh.12234","article-title":"Poor responses to tyrosine kinase inhibitors in a child with precursor B-cell acute lymphoblastic leukemia with SNX2-ABL1 chimeric transcript","author":"Masuzawa","year":"2013","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.leukres.2013.11.017_bib0190","doi-asserted-by":"crossref","first-page":"3405","DOI":"10.1002\/eji.201242530","article-title":"ZNF385B is characteristically expressed in germinal center B cells and involved in B-cell apoptosis","volume":"42","author":"Iijima","year":"2012","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.leukres.2013.11.017_bib0195","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s12185-012-1234-3","article-title":"Effects of insulin-like growth factor-1 on B-cell precursor acute lymphoblastic leukemia","volume":"97","author":"Yamada","year":"2013","journal-title":"Int J Hematol"},{"key":"10.1016\/j.leukres.2013.11.017_bib0200","doi-asserted-by":"crossref","first-page":"18656","DOI":"10.1074\/jbc.272.30.18656","article-title":"Mitosis-specific negative regulation of epidermal growth factor receptor, triggered by a decrease in ligand binding and dimerization, can be overcome by overexpression of receptor","volume":"272","author":"Kiyokawa","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.leukres.2013.11.017_bib0205","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/ng0398-280","article-title":"An intramolecular SH3-domain interaction regulates c-Abl activity","volume":"18","author":"Baril\u00e1","year":"1998","journal-title":"Nat Genet"},{"key":"10.1016\/j.leukres.2013.11.017_bib0210","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jmb.2008.08.040","article-title":"Tyrosine phosphorylation in the SH3 domain disrupts negative regulatory interactions within the c-Abl kinase core","volume":"383","author":"Chen","year":"2008","journal-title":"J Mol Biol"},{"key":"10.1016\/j.leukres.2013.11.017_bib0215","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/sj.leu.2402778","article-title":"The interaction of the Bcr-Abl tyrosine kinase with the Src kinase Hck is mediated by multiple binding domains","volume":"17","author":"Stanglmaier","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2013.11.017_bib0220","doi-asserted-by":"crossref","first-page":"33260","DOI":"10.1074\/jbc.272.52.33260","article-title":"The Src family kinase Hck interacts with Bcr-Abl by a kinase-independent mechanism and phosphorylates the Grb2-binding site of Bcr","volume":"272","author":"Warmuth","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.leukres.2013.11.017_bib0225","doi-asserted-by":"crossref","first-page":"30907","DOI":"10.1074\/jbc.M605902200","article-title":"Src family kinases phosphorylate the Bcr-Abl SH3-SH2 region and modulate Bcr-Abl transforming activity","volume":"281","author":"Meyn","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.leukres.2013.11.017_bib0230","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3324\/haematol.10822","article-title":"Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain","volume":"92","author":"Soverini","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2013.11.017_bib0235","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2003-12-4276","article-title":"Active transport of imatinib into and out of cells: implications for drug resistance","volume":"104","author":"Thomas","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.11.017_bib0240","first-page":"1","article-title":"Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance","volume":"46","author":"Bixby","year":"2009","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.leukres.2013.11.017_bib0245","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/10428190701713689","article-title":"Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia","volume":"49","author":"Li","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.leukres.2013.11.017_bib0250","doi-asserted-by":"crossref","first-page":"13283","DOI":"10.1073\/pnas.0702654104","article-title":"The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib","volume":"104","author":"Hantschel","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.leukres.2013.11.017_bib0255","doi-asserted-by":"crossref","first-page":"18292","DOI":"10.1074\/jbc.M801337200","article-title":"Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib\/nilotinib and dasatinib","volume":"283","author":"Vajpai","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.leukres.2013.11.017_bib0260","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1177\/1947601912458584","article-title":"Structure, regulation, signaling, and targeting of abl kinases in cancer","volume":"3","author":"Hantschel","year":"2012","journal-title":"Genes Cancer"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212613004189?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212613004189?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T04:11:15Z","timestamp":1597119075000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212613004189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S0145212613004189"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2013.11.017","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sensitivity of SNX2-ABL1 toward tyrosine kinase inhibitors distinct from that of BCR-ABL1","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2013.11.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}